Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Alan Meds vs Claya

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.7

Alan Meds

Best for budget-conscious shoppers
★★★3.9

Starting at $99/mo

CompoundedSemaglutideTirzepatideOral Format
Visit Alan Meds
7.0

Claya

Best for Patients seeking a compounded GLP-1 platform with named clinician leadership and named pharmacy partners who want both injectable and oral-tablet form factors, and who are comfortable with the standard 503A-compounded supply chain.
★★★3.5

Starting at $179/mo

Compounded Semaglutide (injectable + oral tablet)Compounded Tirzepatide (injectable + oral tablet)Named medical leadership (Jennifer Habashy NMD MS + Michael Barber MD PhD)Named 503A pharmacy partners (RedRock Pharmacy UT + Healthware House KY)
Visit Claya

Side-by-Side Comparison

FeatureAlan MedsClaya
Overall Score7.7/107.0/10
Starting Price$99/mo$179/mo
Editorial Rating3.9 ★ /53.5 ★ /5
Features5 features8 features
States Available460
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Alan Meds

Pros

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Cons

  • Limited public information on program details

Claya

Pros

  • Two named licensed clinicians (Habashy NMD MS and Barber MD PhD) — rare transparency for a compounded-GLP-1 platform
  • Two named 503A-pattern pharmacy partners with full addresses (RedRock UT + Healthware KY)
  • Both injectable AND oral-tablet compounded formulations offered for both semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on homepage
  • Free expedited shipping included in monthly price

Cons

  • States-served list NOT disclosed on homepage or FAQ — buyers must check at checkout
  • LegitScript certification status NOT displayed on homepage
  • Corporate legal entity (LLC/Inc/PC) NOT disclosed on site or in privacy policy
  • Compounded oral tablets are an aggressive form factor — efficacy data vs injectable semaglutide is weaker (no STEP-equivalent oral compounded trials)
  • Tiered pricing structure (intro vs refill) creates first-month price advantage that disappears at refill

Our Verdict

Winner: Alan MedsScore: 7.7/10

Alan Meds edges out Claya with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Claya remains a solid alternative, especially if you're looking for Patients seeking a compounded GLP-1 platform with named clinician leadership and named pharmacy partners who want both injectable and oral-tablet form factors, and who are comfortable with the standard 503A-compounded supply chain..

Glossary references

Key terms in this article, linked to their canonical definitions.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.